Thelansis

 Polycythemia vera (PV) is a myeloproliferative disorder that produces excessive red blood cells, white blood cells, and platelets, leading to elevated blood viscosity and various associated symptoms. The primary cause is the uncontrolled proliferation of red blood cells, often extending to white blood cells and platelets. While the exact origin of this abnormal stem cell expansion is debated, a somatic mutation known as JAK2-V617F in the JAK2 gene (9p24) is prevalent among most patients. However, less frequently, a somatic mutation in exon 12 of JAK2 can also be found. Symptoms of PV typically manifest insidiously and include headaches, dizziness, vertigo, tinnitus, visual disturbances, and itching after bathing. Patients may also exhibit a flushed appearance in their face, palms, nailbeds, mucosa, and conjunctiva. Complications associated with PV encompass arterial thrombosis (in cerebrovascular, myocardial, or peripheral regions), angina pectoris, intermittent claudications, ven...

  Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by an increase in morphologically normal red cells, white cells and platelets; erythrocytosis is typical. 10% to 30% of patients eventually develop myelofibrosis and marrow failure; acute leukemia occurs spontaneously in 1.0 to 2.5%. The risk of bleeding and arterial or venous thrombosis is increased. Common manifestations include splenomegaly, microvascular events (e.g., transient ischemic attacks, ocular migraine, erythromelalgia), and aquagenic pruritus (itching triggered by exposure to hot water). Eventually, about 10 to 15% of patients progress to a syndrome compatible with primary myelofibrosis but with better survival. The incidence of diagnosed cases of Polycythemia vera (PV) is ~1.75 to 2.27 cases per 100,000 population of men and approximately 1.52 per 100,000 population of women in the USA. Polycythemia vera (PV) prevalence ranges between ~19 to 26 cases per 100,000 people....